U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT07548255) titled 'The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL' on March 29.
Brief Summary: A Single-Arm, Prospective Clinical Study Evaluating the Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined with Obinutuzumab in the First-Line Treatment of Newly Diagnosed Intermediate-to-High-Risk Mantle Cell Lymphoma
Study Start Date: April 20
Study Type: INTERVENTIONAL
Condition:
Intermediate-to-High-Risk Mantle Cell Lymphoma
the Efficacy and Safety
Intervention:
DRUG: Sonrotoclax, Zanubrutinib Combined with Obinutuzumab
The treatment regimen was as follows: In cycle 1 (C1), obinutuzumab 1000 mg was a...